Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 11, 2007, Pages 1369-1379

  Siegal, Deborah ^a   Keller, Anne ^a   Xu, Wei ^b   Bhuta, Sandeep ^a   Kim, Dong Hwan ^a   Kuruvilla, John ^a   Lipton, Jeffrey H ^a   Messner, Hans ^a   Gupta, Vikas ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Allogeneic; Neurologic; PRES; Risk factors; Stem cell transplant; Survival

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GADOLINIUM; IMATINIB; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEATH; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; RECIPIENT; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SEIZURE; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; BRAIN DISEASES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; ONTARIO; REGISTRIES; RETROSPECTIVE STUDIES; SEX FACTORS; SYNDROME; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 35348910742     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.07.013     Document Type: Article

References (37)

1. Antonini G., Ceschin V., Morino S., et al. Early neurologic complications following allogeneic bone marrow transplant for leukemia: a prospective study. Neurology 50 (1998) 1441-1445
2. de Brabander C., Cornelissen J., Smitt P.A., Vecht C.J., and van den Bent M.J. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry 68 (2000) 36-40
3. Faraci M., Lanino E., Dini G., et al. Severe neurologic complications after hematopoietic stem cell transplantation in children. Neurology 59 (2002) 1895-1904
4. Gallardo D., Ferra C., Berlanga J.J., et al. Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant 18 (1996) 1135-1139
5. Graus F., Saiz A., Sierra J., et al. Neurologic complications of autologous and allogeneic bone marrow transplantation in patients with leukemia: a comparative study. Neurology 46 (1996) 1004-1009
6. Guerrero A., Perez-Simon J.A., Gutierrez N., et al. Neurological complications after autologous stem cell transplantation. Eur Neurol 41 (1999) 48-50
7. Iguchi A., Kobayashi R., Yoshida M., et al. Neurological complications after stem cell transplantation in childhood. Bone Marrow Transplant 24 (1999) 647-652
8. Kishi Y., Miyakoshi S., Kami M., et al. Early central nervous system complications after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 561-568
9. Reece D.E., Frei-Lahr D.A., Shepherd J.D., et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant 8 (1991) 393-401
10. Sostak P., Padovan C.S., Yousry T.A., Ledderose G., Kolb H.J., and Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology 60 (2003) 842-848
11. Uckan D., Cetin M., Yigitkanli I., et al. Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant 35 (2005) 71-76
12. Mohrmann R.L., Mah V., and Vinters H.V. Neuropathologic findings after bone marrow transplantation: an autopsy study. Hum Pathol 21 (1990) 630-639
13. Bleggi-Torres L.F., de Medeiros B.C., Werner B., et al. Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bone Marrow Transplant 25 (2000) 301-307
14. Bartynski W.S., Zeigler Z.R., Shadduck R.K., and Lister J. Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation. Neurocrit Care 3 (2005) 33-45
15. Chohan R., Vij R., Adkins D., et al. Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. Br J Haematol 123 (2003) 110-113
16. Bartynski W.S., Zeigler Z., Spearman M.P., Lin L., Shadduck R.K., and Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol 22 (2001) 1901-1914
17. Trullemans F., Grignard F., Van Camp B., and Schots R. Clinical findings and magnetic resonance imaging in severe cyclosporine-related neurotoxicity after allogeneic bone marrow transplantation. Eur J Haematol 67 (2001) 94-99
18. Bartynski W.S., Zeigler Z.R., Shadduck R.K., and Lister J. Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. AJNR Am J Neuroradiol 25 (2004) 261-269
19. Zimmer W.E., Hourihane J.M., Wang H.Z., and Schriber J.R. The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation. AJNR Am J Neuroradiol 19 (1998) 601-660 [discussion 9-10]
20. Cohen R.B., Abdallah J.M., Gray J.R., and Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med 118 (1993) 114-116
21. Spriggs D.R., Stopa E., Mayer R.J., Schoene W., and Kufe D.W. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 46 (1986) 5953-5958
22. Vidarsson B., Mosher D.F., Salamat M.S., Isaksson H.J., and Onundarson P.T. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol 70 (2002) 51-54
23. Warrell Jr. R.P., and Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4 (1986) 74-79
24. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331 (1994) 896-903
25. Fyles G.M., Messner H.A., Lockwood G., et al. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate. Bone Marrow Transplant 8 (1991) 453-463
26. Gupta V., Yi Q.L., Brandwein J., et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant 33 (2004) 397-404
27. Kiss T.L., Panzarella T., Messner H.A., et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 31 (2003) 73-78
28. Gupta V., Chun K., Yi Q.L., et al. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 103 (2005) 2082-2090
29. Gupta V., Daly A., Lipton J.H., et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant 11 (2005) 764-772
30. Casey S.O., Sampaio R.C., Michel E., and Truwit C.L. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 21 (2000) 1199-1206
31. Hinchey J., Chaves C., Appignani B., et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334 (1996) 494-500
32. Gooley T.A., Leisenring W., Crowley J., and Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
33. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
34. Wong R., Beguelin G.Z., de Lima M., et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 122 (2003) 128-134
35. Erer B., Polchi P., Lucarelli G., et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. Bone Marrow Transplant 18 (1996) 157-162
36. Lucey M.R., Kolars J.C., Merion R.M., Campbell D.A., Aldrich M., and Watkins P.B. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335 (1990) 11-15
37. Thompson C.B., June C.H., Sullivan K.M., and Thomas E.D. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 2 (1984) 1116-1120